Press Release: Romark Laboratories, L.C : Romark's Vanguard Co-V Clinical Trial Published in Lancet's eClinicalMedicine

TAMPA, Fla., March 9, 2022 /PRNewswire/ -- Romark announced today that results of its Vanguard Co-V clinical trial of NT-300 (nitazoxanide extended-release tablets, 300 mg) for treatment of mild or moderate COVID-19 have been published in Lancet's eClinicalMedicine.¹ NT-300 is an oral...